Systemic medications, particularly selective beta blockers and calcium channel blockers, can significantly influence intraocular pressure (IOP) over time, according to study results published in ...

Standalone canaloplasty and trabeculotomy can deliver meaningfully reduced IOP in the long term and require fewer topical therapy agents.

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Measurements at baseline (1988–90) and 5 year follow up of systemic blood pressures, intraocular pressures, and history of use of blood pressure medications. Results: Intraocular pressures were ...

Patients with varying stages of glaucoma saw no significant difference in outcomes between standard and enhanced monofocal ...

According to a new study, 70% of astronauts who have spent between six and 12 months aboard the International Space Station ...

Aims To investigate the change that occurs in intraocular pressure (IOP) and ocular pulse amplitude (OPA) with accommodation in young adult myopes and emmetropes. Methods Fifteen progressing myopic ...

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, ...

Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...

Continuous positive airway pressure (CPAP) therapy, which is the most common treatment for obstructive sleep apnea (OSA), may significantly increase intraocular pressure (IOP) in the long term and ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).